loading page

Quality of life assessment among Cystic Fibrosis patients in Palestine: Cross Sectional Study
  • +2
  • Samya Salah,
  • Nisreen Rumman ,
  • Amal Nassar,
  • Maher Khdour,
  • Hussein Hallak
Samya Salah
Al-Quds University

Corresponding Author:[email protected]

Author Profile
Nisreen Rumman
Makassed Hospital
Author Profile
Amal Nassar
Caritas Baby Hospital
Author Profile
Maher Khdour
Al-Quds University
Author Profile
Hussein Hallak
Al-Quds University
Author Profile


Objective: To assess the quality of life (QoL) of Cystic fibrosis (CF) patients in West Bank, Palestine using the Cystic Fibrosis Questionnaire-Revised (CFQ-R) form. Method: A cross-sectional study involving application of CFQ-R questionnaire in CF patients attending pediatric pulmonology clinic at Caritas Baby Hospital (CBH). Their health status was assessed by measuring different parameters including pulmonary function test (FEV1) and body mass index (BMI). Results: The sample consisted of 77 patients from 58 families: 46.75% were males. Mean age was 10.7 years. Patients were divided into three groups by age in years: group I (< 6), II (6-13), and III (≥ 14). The highest and lowest CFQ scores were for the eat domain in group III (55.56 ± 22.49) and the body domain in group II (14.48 ± 17.67), respectively. Illness severity as measured by FEV1 mean value 69.6. BMI mean value of 15.998. The overall mean age at time of diagnosis in our sample was 4.16 years (± 6.239). The study showed that 1.7% of families had four affected siblings and 21% had death cases related to CF. Finally, all parameters for CF patients in West Bank, Palestine appear to be noticeably lower than those reported in other countries. Conclusions: quality of life for patients with CF is poor relative to international standards, the medications used including hypertonic saline and Gentamycin IV form used as nebulizer solution are not first line therapies around the world. This study illustrates the need of new therapies for CF patients in Palestine.
07 Sep 2021Submitted to Pediatric Pulmonology
08 Sep 2021Submission Checks Completed
08 Sep 2021Assigned to Editor
09 Sep 2021Reviewer(s) Assigned
21 Oct 2021Review(s) Completed, Editorial Evaluation Pending
23 Oct 2021Editorial Decision: Revise Major
08 Feb 20221st Revision Received
21 Feb 2022Assigned to Editor
21 Feb 2022Submission Checks Completed
21 Feb 2022Reviewer(s) Assigned
10 Mar 2022Review(s) Completed, Editorial Evaluation Pending
13 Mar 2022Editorial Decision: Revise Minor
30 Jan 20232nd Revision Received
31 Jan 2023Submission Checks Completed
31 Jan 2023Assigned to Editor
31 Jan 2023Review(s) Completed, Editorial Evaluation Pending
31 Jan 2023Reviewer(s) Assigned
17 Feb 2023Editorial Decision: Accept